945
Participants
Start Date
December 13, 2019
Primary Completion Date
November 30, 2023
Study Completion Date
November 30, 2023
Blood Draw
Participants will have blood drawn at enrollment, the first tumor assessment, and at disease progression or end of therapy.
West Clinic, New York
National Translational Research Group, Port Jefferson Station
Hematology Oncology Associates of Central New York, East Syracuse
Hematology Oncology Associates of Fredericksburg, Inc., Fredericksburg
Virginia Cancer Institute - Richmond, Richmond
Piedmont Cancer Institute, PC, Atlanta
University Cancer & Blood Center, LLC; Research, Athens
SCRI Florida Cancer Specialists PAN, Tallahassee
Florida Cancer Specialists, West Palm Beach
Florida Cancer Specialist, North Region, St. Petersburg
Alabama Oncology, Birmingham
Clearview Cancer Institute, Huntsville
Tennessee Oncology, Nashville
SCRI Tennessee Oncology Chattanooga, Chattanooga
Jackson Oncology Associates, PLLC, Jackson
Fort Wayne Med Oncology & Hematology Inc, Fort Wayne
Cancer & Hematology Centers of Western Michigan, Grand Rapids
Southeast Nebraska Cancer Ctr, Lincoln
Oklahoma Cancer Specialists and Research Institute, Tulsa
Ironwood Cancer & Research Centers, Chandler
Yale University, New Haven
Florida Cancer Specialists; Department of Oncology, Fort Myers
Regional Cancer Care Associates LLC, Central Jersey Division, East Brunswick
Lead Sponsor
Flatiron Health, Inc.; Foundation Medicine, Inc.
UNKNOWN
Genentech, Inc.
INDUSTRY